·February 9, 2023·1 min read

JPM23: After rock climbing in biotech, Novartis’ CMO is back to support hopeful hike to US summit

JPM23: After rock climbing in biotech, Novartis' CMO is back to support hopeful hike to US summit

Novartis’ Shreeram Aradhye is back after a stint in biotech, but he doesn’t think the downturn offers a plethora of great assets for pharma’s choosing

This content was originally published here.